US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
SNDK
$1,704.16
▼-0.92%
AAPL
$332.89
▼-0.24%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
SNDK
$1,704.16
▼-0.92%
AAPL
$332.89
▼-0.24%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Karuna Therapeutics, Inc. - Common Stock
(NQ:
KRTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Karuna Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Analyst Ratings for Karuna Therapeutics
↗
May 24, 2022
Karuna Therapeutics (NASDAQ:KRTX) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Karuna Therapeutics to Host Virtual Event Highlighting Clinical Program for Psychosis in Alzheimer’s Disease
May 18, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics: Q1 Earnings Insights
↗
May 05, 2022
Karuna Therapeutics (NASDAQ:KRTX) reported its Q1 earnings results on Thursday, May 5, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Karuna Therapeutics Reports First Quarter 2022 Financial Results and Provides General Business Update
May 05, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics to Present at the 2022 RBC Capital Markets Global Healthcare Conference
May 03, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
What 4 Analyst Ratings Have To Say About Karuna Therapeutics
↗
April 27, 2022
Karuna Therapeutics (NASDAQ:KRTX) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022
↗
March 31, 2022
Upgrades
Via
Benzinga
Amid Russia's Invasion On Ukraine, Karuna Therapeutics Withdraws Guidance On Late-Stage Schizophrenia Trial
↗
February 24, 2022
According to an SEC filing, Karuna Therapeutics Inc (NASDAQ: KRTX) is withdrawing its prior guidance for the timing of topline data for its Phase 3 EMERGENT-3 trial...
Via
Benzinga
Karuna Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides General Business Update
February 24, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference
February 01, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
This Metaverse Stock Will Be Featured On 'Mad Money' Wednesday Night
↗
December 01, 2021
Unity Software Inc (NYSE:U) CEO John Riccitiello
Via
Benzinga
Karuna Therapeutics Appoints Charmaine Lykins as Chief Commercial Officer
November 29, 2021
From
Karuna Therapeutics, Inc.
Via
Business Wire
Week In Review: Zai Lab Announces Two In-Licensings With Total Value Of $800 Million
↗
November 13, 2021
Shanghai Zai Lab announced two major in-licensings: a $615 million deal for two cancer drugs from Blueprint Medicines and a $187 million agreement for a psychiatric drug from Karuna Therapeutics.
Via
Talk Markets
Why Karuna Therapeutics Stock Tumbled This Week
↗
November 12, 2021
Investors apparently weren't thrilled by the company's licensing agreement with Zai Lab.
Via
The Motley Fool
Zai Lab Inks Back To Back Licensing Agreements For Cancer And Psychiatric Candidates
↗
November 09, 2021
Zai Lab Limited (NASDAQ: ZLAB) and Blueprint Medicines Corporation (NASDAQ: BPMC) have announced an exclusive collaboration and license agreement in...
Via
Benzinga
76 Biggest Movers From Yesterday
↗
November 11, 2021
Gainers Expensify, Inc. (NASDAQ: EXFY) jumped 52.1% to settle at $41.06 on Wednesday after the company priced its IPO at $27 per share. RenovoRx, Inc. (NASDAQ: RNXT) shares...
Via
Benzinga
Topics
Initial Public Offering
PureTech Founded Entity Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China
November 09, 2021
From
PureTech Health plc
Via
Business Wire
Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China
November 09, 2021
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics to Present at Upcoming Investor Conferences
November 08, 2021
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics Reports Third Quarter 2021 Financial Results and Provides General Business Update
November 04, 2021
From
Karuna Therapeutics, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
↗
September 30, 2021
Upgrades For Cabot Oil & Gas Corp (NYSE:COG),...
Via
Benzinga
Karuna Therapeutics to Present at 2021 Virtual Wells Fargo Healthcare Conference
September 01, 2021
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics to Present at the Citi 16th Annual BioPharma Virtual Conference
August 31, 2021
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics Reports Second Quarter 2021 Financial Results and Provides General Business Update
August 05, 2021
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics to Present at 2021 Wedbush PacGrow Healthcare Virtual Conference
August 03, 2021
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics Announces Results from Phase 1b Trial Evaluating the Safety and Tolerability of KarXT in Healthy Elderly Volunteers
June 23, 2021
From
Karuna Therapeutics, Inc.
Via
Business Wire
Biotechs Ready To Roar
↗
June 13, 2021
The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector...
Via
Talk Markets
Karuna Therapeutics to Present at Upcoming Investor Conferences
June 02, 2021
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics Reports First Quarter 2021 Financial Results and Provides General Business Update
May 06, 2021
From
Karuna Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
